White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Patients HCP
This site is for US residents only.
Starting SCEMBLIX. For newly diagnosed Ph+ CML in chronic phase. Kat was diagnosed with Ph+ CML at age 19 and has tried multiple TKIs. Kat, real SCEMBLIX patient. Kat was compensated for her time.

In a head-to-head clinical study of adults with newly diagnosed Ph+ CML in chronic phase

SCEMBLIX had better response rates

More people achieved MMR with SCEMBLIX than with commonly used TKIs* at 48 weeks

Major molecular response (MMR) is a treatment goal that is reached when the abnormal gene in the blood is ≤0.1% of the level of BCR::ABL1 gene measured at your CML diagnosis.

Percentage of people who achieved MMR at nearly 1 year (48 weeks). SCEMBLIX vs. Commonly Used TKIs: SCEMBLIX, 68% (136 of 201 patients). Commonly used TKIs, 49% (100 of 204 patients). SCEMBLIX vs. Gleevec: SCEMBLIX, 69% (70 of 101 patients). Gleevec, 40% (41 of 102 patients).

For adult patients with newly diagnosed Ph+ CML in chronic phase, SCEMBLIX is the only medication that was compared against all commonly used TKIs: GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel® (dasatinib), and Bosulif ® (bosutinib).

SCEMBLIX worked fast

In this study, 201 patients took SCEMBLIX while 204 patients took commonly used TKIs.*

The time by which half of the patients in each group achieved major molecular response (MMR). The majority of patients on SCEMBLIX reached MMR almost three months earlier.

If you're an adult with newly diagnosed Ph+ CML in chronic phase, ask your doctor if SCEMBLIX may be the right treatment to start out on.

2x fewer patients on SCEMBLIX stopped treatment due to side effects at 48 weeks

By 48 weeks, 90% of patients on SCEMBLIX were still on treatment vs 81% of patients on the most commonly used TKIs.*

Percentage of people who stopped treatment specifically due to side effects at 48 weeks, SCEMBLIX vs. Commonly Used TKIs. Two times fewer patients on SCEMBLIX stopped treatment due to side effects. SCEMBLIX, 4.5% (9 of 200) patients. Commonly used TKIs, 10.4% (21 out of 201 patients).

Common side effects

In this clinical study, the most common side effect reported (≥ 20%) with SCEMBLIX was pain in the muscles, bones, or joints.

These are not all of the possible side effects of SCEMBLIX.

Review the serious and most common side effects of SCEMBLIX. Learn more

Question mark icon

Ask your doctor about SCEMBLIX as your first treatment
 

Questions to ask your doctor about SCEMBLIX: 
 

  1. How is SCEMBLIX different from other medications that treat Ph+ CML-CP? 

  2. When might I expect to see results with SCEMBLIX?

  3. What are the most serious and common side effects of SCEMBLIX?

  4. How will I know if SCEMBLIX is working?

Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; TKIs, tyrosine kinase inhibitors.

*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.

†Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.